NCR3 and neoplasm: Using an NKp30 reporter cell line and B7-H6-expressing P815 tumor cells, they concluded that the bulky 17B1.3 antibody acts by sterically interfering with close cell–cell contacts at the NK cell–target cell interface, thereby blocking immunological synapse formation and NK cell activation [40].